Related Experiment Video
Updated: Jun 22, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Radiochemotherapy for bladder cancer.
1Department of Radiation Oncology, University Hospitals Erlangen, Universitätsstrasse 27, Erlangen, Germany. oliver.ott@uk-erlangen.de
Clinical Oncology (Royal College of Radiologists (Great Britain))
|July 1, 2009
Summary
Multimodality treatment offers bladder preservation for muscle-invasive bladder cancer, achieving survival rates comparable to cystectomy. Careful patient selection and complete tumor resection are key for successful organ preservation.
Area of Science:
- Oncology
- Urology
Background:
- Standard treatment for muscle-invasive bladder cancer (MIBC) is cystectomy.
- Multimodality treatment (MMT) offers an alternative, potentially preserving the bladder.
Purpose of the Study:
- To evaluate the efficacy of MMT for MIBC organ preservation.
- To identify prognostic factors for bladder preservation and overall survival.
Main Methods:
- Analysis of prospective series including over 1000 patients treated with MMT.
- Inclusion criteria: transurethral resection, radiation therapy, chemotherapy, and deep regional hyperthermia.
- Multivariate analysis to determine prognostic factors.
Main Results:
- Five-year overall survival rates of 50-60% reported with MMT.
- Approximately 75% of survivors maintained their bladders.
- Complete transurethral resection of bladder tumor (TURBT) identified as a strong prognostic factor for survival.
Conclusions:
- MMT provides comparable survival to cystectomy for MIBC, with a high rate of bladder preservation.
- Patient selection criteria (tumor size, stage, complete TURBT, no obstruction/metastasis) are crucial.
- Future research should focus on optimizing radiation, chemotherapy, and molecular markers for patient selection.
